Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
about
Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and PerspectivesIntracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in ratsVEGF gene therapy: therapeutic angiogenesis in the clinic and beyondAngiomyogenesis for myocardial repair.Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardiumVirus-mediated gene transfer to induce therapeutic angiogenesis: where do we stand?Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).Treatment of inoperable coronary disease and refractory angina: spinal stimulators, epidurals, gene therapy, transmyocardial laser, and counterpulsation.Spinal cord stimulation: a comparison of efficacy versus other novel treatments for refractory angina pectoris.Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct modelGene therapy for therapeutic angiogenesis in critically ischaemic lower limb - on the way to the clinic.Vascular growth factor and gene therapy to induce new vessels in the ischemic myocardium. Therapeutic angiogenesis.Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?Clinical applications of cardiovascular angiogenesis.Therapeutic angiogenesis in critical limb and myocardial ischemia.Molecular medicine for the cardiac surgeon.Basic principles of angiogenesis for the interventional cardiologist.Designer blood vessels and therapeutic revascularizationThe role of TGFβ1 and LRG1 in cardiac remodelling and heart failure.Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease.Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis.Gene therapy for cardiovascular angiogenesis.Therapeutic angiogenesis for myocardial ischemia.The evolution of heart gene delivery vectorsTherapeutic angiogenesis using vascular endothelial growth factor.Cardiovascular gene delivery: The good road is awaitingReappraisal of recent clinical trials of angiogenic therapy in myocardial ischemia.Targeting vascular endothelial growth factor in angina therapy.Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy.Gene targeting in ischemic heart disease and failure: translational and clinical studies.Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease.Gene and cell therapy for chronic ischaemic heart disease.Therapeutic myocardial angiogenesisNonviral vector gene modification of stem cells for myocardial repair.Targets for regulating angiogenesis in the ageing endothelium.Radiolabeled arginine-glycine-aspartic acid peptides to image angiogenesis in swine model of hibernating myocardiumExercise training and peripheral arterial disease.Factors determining heterogeneity in coronary collateral development: A clinical perspective.Gene therapy to treat cardiovascular disease.VEGF 165 gene therapy for patients with refractory angina: mobilization of endothelial progenitor cells
P2860
Q26769595-EA9EF223-489C-4610-94CC-25491D2D0A4DQ28212065-396CACDE-6D64-47E8-9D05-E52692925641Q28260984-DD910EF2-2F16-4BEC-8733-9F2430178090Q30480151-7C22ADD8-9B8F-4A48-A29A-C363542086A2Q30487688-773E10A2-2EFD-4E0B-B2FE-70B8994EFE34Q30489689-FDC2DCBF-0171-46E1-9948-FD067002D4C4Q30758542-7E60445B-2447-4963-A166-899CD3F67B30Q31112721-7022984F-08E8-4338-82A8-1043AA90D8AFQ33264719-0F6DECEC-D239-4B39-ABBA-34C6D55A6B54Q33509006-D4368B1D-8C48-48F7-99A2-CB52E632CF77Q34319721-2DC2A425-0A4A-4259-8348-4D7A6DEB6061Q34481171-40164EB8-8F14-4122-9967-CB7A5FDD4E6AQ34482530-9B619E1D-5214-4102-BA6A-8C67D0DB2801Q34582629-5277AC97-C1E7-4F10-AFC2-B0D263ADED88Q34675242-E84611D7-BA5F-4580-851E-0D3B1FF6E791Q34803109-DBE8AEC1-10C2-4717-8256-FF038BC26AF4Q35019038-E2111E89-FF96-4EB4-9FBF-70084A090ED9Q35045765-C816939C-2E3E-407E-8353-E66D8EFCE349Q35065245-19BF8F53-14B4-4508-93B0-29DAF10EE7C6Q35070251-165DE9A5-C004-4710-92BB-E1C3E91FCDEAQ35101166-26E76F80-78E6-42CD-A67D-C87E53A3D050Q35164797-662F4A77-54E4-4406-BDE1-B43D42F56598Q35777375-19295186-5FD1-46FD-AE07-82CA5A199B8FQ35799722-EF69B7E2-77DC-4DD0-A10C-8BB42379602BQ35814821-32DFF78B-A972-4D03-9BA8-F18C0A82DC4EQ35915765-16B76C0B-1EB6-429E-9304-9C9F00B48F8CQ36081298-33B7749F-B0A6-4DC2-A6B3-4F76047F3C6EQ36379360-70B3F031-5CF6-4D1C-AEE7-06B5FE87A0A0Q36480080-D06A8668-2961-4512-80A1-1DC0A772A509Q36617570-A3297D7A-3B34-40C3-9080-8BA46E18691BQ36634798-D00107A4-8101-4599-8C52-B1FFB54DF0CFQ36675432-2E3E9F69-292B-4A16-B5F9-27D3C61C1E59Q36976439-B012E4A9-5D60-4C97-BDBC-DB6E021A6D32Q36994178-A33F7F6F-7BF9-4F74-AFA1-5AB6FC6EC2FBQ37008834-1ADCD95E-D733-46EA-9975-9649AFBBAE1CQ37085665-CA7E09DC-D4CA-4FCB-9A3A-BCCC61B15A07Q37157213-3393AA41-1CD2-4402-818E-82FEFBC066C4Q37284651-84FFFBB8-ED1D-4E9A-8FB4-0A070E8B3A0BQ37310450-C1AB4723-50A0-4D38-928C-3E3172517CA1Q37720734-66303FC3-8EDE-4302-A172-FDFD1CF43369
P2860
Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Gene therapy with vascular end ...... rable coronary artery disease.
@en
Gene therapy with vascular end ...... rable coronary artery disease.
@nl
type
label
Gene therapy with vascular end ...... rable coronary artery disease.
@en
Gene therapy with vascular end ...... rable coronary artery disease.
@nl
prefLabel
Gene therapy with vascular end ...... rable coronary artery disease.
@en
Gene therapy with vascular end ...... rable coronary artery disease.
@nl
P2093
P1476
Gene therapy with vascular end ...... rable coronary artery disease.
@en
P2093
Losordo DW
P304
830-6; discussion 836-7
P356
10.1016/S0003-4975(99)00807-3
P407
P577
1999-09-01T00:00:00Z